CN103108637B - 静脉内施用格列苯脲和其他药物的方法 - Google Patents

静脉内施用格列苯脲和其他药物的方法 Download PDF

Info

Publication number
CN103108637B
CN103108637B CN201180044843.6A CN201180044843A CN103108637B CN 103108637 B CN103108637 B CN 103108637B CN 201180044843 A CN201180044843 A CN 201180044843A CN 103108637 B CN103108637 B CN 103108637B
Authority
CN
China
Prior art keywords
glibenclamide
drug
glyburide
hours
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180044843.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN103108637A (zh
Inventor
S·M·雅各布森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Remidi Pharmaceuticals
Original Assignee
Bicenza Chesa
Remidi Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bicenza Chesa, Remidi Pharmaceuticals filed Critical Bicenza Chesa
Priority to CN201810945946.3A priority Critical patent/CN109172363A/zh
Publication of CN103108637A publication Critical patent/CN103108637A/zh
Application granted granted Critical
Publication of CN103108637B publication Critical patent/CN103108637B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Anesthesiology (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
CN201180044843.6A 2010-07-19 2011-07-18 静脉内施用格列苯脲和其他药物的方法 Active CN103108637B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810945946.3A CN109172363A (zh) 2010-07-19 2011-07-18 静脉内施用格列苯脲和其他药物的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36568910P 2010-07-19 2010-07-19
US61/365,689 2010-07-19
PCT/US2011/044397 WO2012012347A2 (en) 2010-07-19 2011-07-18 Methods of intravenous administration of glyburide and other drugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810945946.3A Division CN109172363A (zh) 2010-07-19 2011-07-18 静脉内施用格列苯脲和其他药物的方法

Publications (2)

Publication Number Publication Date
CN103108637A CN103108637A (zh) 2013-05-15
CN103108637B true CN103108637B (zh) 2018-09-14

Family

ID=45497399

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180044843.6A Active CN103108637B (zh) 2010-07-19 2011-07-18 静脉内施用格列苯脲和其他药物的方法
CN201810945946.3A Pending CN109172363A (zh) 2010-07-19 2011-07-18 静脉内施用格列苯脲和其他药物的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810945946.3A Pending CN109172363A (zh) 2010-07-19 2011-07-18 静脉内施用格列苯脲和其他药物的方法

Country Status (7)

Country Link
US (9) US8946293B2 (https=)
EP (3) EP3586850A1 (https=)
JP (5) JP6188021B2 (https=)
KR (8) KR20190031592A (https=)
CN (2) CN103108637B (https=)
CA (3) CA3101711C (https=)
WO (1) WO2012012347A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102481271A (zh) 2009-05-11 2012-05-30 博格生物系统有限责任公司 利用表观代谢转变剂、多维细胞内分子或环境影响剂治疗代谢障碍的方法
KR20190031592A (ko) 2010-07-19 2019-03-26 바이오젠 체사피크 엘엘씨 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법
LT2616064T (lt) 2010-10-21 2019-11-25 Rtu Pharmaceuticals Llc Parengtos naudoti ketorolako kompozicijos
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
WO2013169939A2 (en) 2012-05-08 2013-11-14 Aeromics, Llc New methods
NZ713868A (en) 2013-04-08 2021-12-24 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
KR102370843B1 (ko) * 2013-09-04 2022-03-04 버그 엘엘씨 코엔자임 q10의 연속주입에 의한 암치료 방법
US20160279155A1 (en) 2013-11-06 2016-09-29 Aeromics, Inc. Novel formulations
US10900040B2 (en) 2015-05-29 2021-01-26 University Of Maryland, Baltimore Methods of reducing or preventing intimal damage caused by mechanical stimulation of endothelial cells
WO2017062765A1 (en) * 2015-10-07 2017-04-13 Remedy Pharmaceuticals, Inc. Methods of treating injuries or conditions related to cns edema
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
CN109689037B (zh) 2016-07-29 2022-09-13 生物切萨皮克有限责任公司 利用sur1-trpm4通道抑制剂的医学治疗方法
US11382881B2 (en) 2017-05-05 2022-07-12 Nino Sorgente Methods and compositions for diagnosing and treating glaucoma
WO2018204721A1 (en) 2017-05-05 2018-11-08 Nino Sorgente Methods and compositions for improving eye health
CN108078999B (zh) * 2017-12-22 2020-08-14 沈阳药科大学 用于防治缺血性脑卒中的药物组合物及其制备方法和用途
CN115836050B (zh) 2020-07-17 2024-12-20 上海森辉医药有限公司 磺酰脲类衍生物及其医药用途
US12251388B1 (en) 2024-05-09 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
US12251389B1 (en) 2024-04-22 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1960735A (zh) * 2004-05-20 2007-05-09 代阿麦迪卡股份有限公司 药物组合在治疗胰岛素抗性中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856360A (en) * 1996-05-03 1999-01-05 Children's Hospital Medical Center Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
DE10300323A1 (de) * 2003-01-09 2004-10-14 Baxter Healthcare S.A. Sicherheitsbehälter mit erhöhter Bruch und Splitterfestigkeit sowie kontaminationsfreier Außenfläche für biologisch aktive Substanzen und Verfahren zu deren Herstellung
US20080220441A1 (en) * 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
EP2438913B1 (en) 2002-03-20 2020-05-06 University of Maryland, Baltimore A non-selective cation channel in neural cells and compounds that block the channel for use in treating brain swelling
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
US20040073192A1 (en) * 2002-10-15 2004-04-15 Flament-Garcia Mary Jane Intravenous fluid delivery set
US20050148928A1 (en) * 2003-12-31 2005-07-07 Medtronic Minimed, Inc. Multiple layer tubing and method of making same
EP1802313B1 (en) * 2004-09-18 2010-11-03 University of Maryland, Baltimore Therapeutic agents trageting the ncca-atp channel and methods of use thereof
JP5085326B2 (ja) * 2004-09-18 2012-11-28 ユニバーシティ オブ メリーランド，ボルチモア ＮＣＣａ−ＡＴＰチャネルを標的とする処置剤およびその使用方法
AU2005322136B2 (en) * 2004-12-23 2011-01-06 Hospira, Inc. Port closure system for intravenous fluid container
BRPI0715279A2 (pt) 2006-09-29 2013-06-11 Infa Sa sistema de embalagem, sistema de embalagem para uma composiÇço farmacÊutica, mÉtodo para transferir uma composiÇço farmcÊutica para administraÇço por infusço intravenosa, uso de um sistema de embalagem, kit para administraÇço parenteral de fÁrmacos com um acesso intravenoso e kit admnistraÇço parenteral de princÍpios ativos
CA2691199C (en) * 2007-06-22 2017-09-12 Marc J. Simard Inhibitors of ncca-atp channels for therapy
US20110034560A1 (en) * 2008-01-29 2011-02-10 Sven Jacobson Liquid formulations of compounds active at sulfonylurea receptors
CN101229316B (zh) * 2008-01-31 2010-08-25 广东药学院 一种知母提取物
KR20190031592A (ko) 2010-07-19 2019-03-26 바이오젠 체사피크 엘엘씨 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1960735A (zh) * 2004-05-20 2007-05-09 代阿麦迪卡股份有限公司 药物组合在治疗胰岛素抗性中的应用

Also Published As

Publication number Publication date
JP6795571B2 (ja) 2020-12-02
JP6188021B2 (ja) 2017-08-30
KR101917975B1 (ko) 2018-11-13
KR20170118960A (ko) 2017-10-25
KR20230165363A (ko) 2023-12-05
US20190328653A1 (en) 2019-10-31
AU2011279878A1 (en) 2013-03-07
US10786445B2 (en) 2020-09-29
WO2012012347A2 (en) 2012-01-26
KR20180123176A (ko) 2018-11-14
JP6506335B2 (ja) 2019-04-24
US8946293B2 (en) 2015-02-03
CN109172363A (zh) 2019-01-11
CA2806069A1 (en) 2012-01-26
CA3225438A1 (en) 2012-01-26
US12226521B2 (en) 2025-02-18
CA3101711A1 (en) 2012-01-26
US11559481B2 (en) 2023-01-24
EP3586850A1 (en) 2020-01-01
US20210154135A1 (en) 2021-05-27
WO2012012347A3 (en) 2012-05-10
JP2016020393A (ja) 2016-02-04
JP2020073595A (ja) 2020-05-14
JP2019038855A (ja) 2019-03-14
US9561176B2 (en) 2017-02-07
US20170333340A1 (en) 2017-11-23
US20130203853A1 (en) 2013-08-08
US20170348227A1 (en) 2017-12-07
KR20220000943A (ko) 2022-01-04
US9254259B2 (en) 2016-02-09
CA3101711C (en) 2024-02-13
KR20200054319A (ko) 2020-05-19
KR20190031592A (ko) 2019-03-26
KR20130133165A (ko) 2013-12-06
US20250221924A1 (en) 2025-07-10
KR20250026419A (ko) 2025-02-25
US10052280B2 (en) 2018-08-21
CN103108637A (zh) 2013-05-15
EP2595633A2 (en) 2013-05-29
US20230414489A1 (en) 2023-12-28
US10391053B2 (en) 2019-08-27
EP3339190A1 (en) 2018-06-27
CA2806069C (en) 2021-01-19
US20150157560A1 (en) 2015-06-11
EP2595633A4 (en) 2014-01-22
JP6179574B2 (ja) 2017-08-16
US20160030370A1 (en) 2016-02-04
JP2017105846A (ja) 2017-06-15
JP2013532658A (ja) 2013-08-19

Similar Documents

Publication Publication Date Title
CN103108637B (zh) 静脉内施用格列苯脲和其他药物的方法
AU2011279878B2 (en) Methods of intravenous administration of glyburide and other drugs
HK40002343A (en) Methods of intravenous administration of glyburide and other drugs
HK40020325A (en) Methods of intravenous administration of glyburide and other drugs
HK1185276B (en) Methods of intravenous administration of glyburide and other drugs
HK1185276A (en) Methods of intravenous administration of glyburide and other drugs

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1185276

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20180809

Address after: Massachusetts, USA

Applicant after: Bicenza Chesa

Address before: American New York

Applicant before: Remidi Pharmaceuticals

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20240703

Address after: USA New York

Patentee after: Remidi Pharmaceuticals

Country or region after: U.S.A.

Address before: Massachusetts, USA

Patentee before: Bicenza Chesa

Country or region before: U.S.A.

TR01 Transfer of patent right